Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 8, 2005, Pages 901-909

  Mirallié, Eric ^a   Saï Maurel, Catherine ^a   Faivre Chauvet, Alain ^a   Regenet, Nicolas ^b   Chang, Chien Hsing ^c   Goldenberg, David M ^c   Chatal, Jean François ^a   Barbet, Jacques ^a   Thedrez, Philippe ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c IBC Pharmaceuticals Inc   (United States)

Author keywords

Biotin avidin; Carcinoembryonic antigen; Chase; Pretargeting

Indexed keywords

AVIDIN; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; HAPTEN; MONOCLONAL ANTIBODY; N ALPHA (DIETHYLENETRIAMINE N,N,N',N'' TETRAACETIC ACID N''' ACETYL)TYROSYL N EPSILON (DIETHYLENETRIAMINE N,N,N',N'' TETRAACETIC ACID N''' ACETYL)LYSINE INDIUM I 125; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; BLOOD SAMPLING; BONE MARROW; CANCER GRAFT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY; LIVER; MOUSE; NONHUMAN; PLASMA CLEARANCE; RADIOIMMUNOTHERAPY; SPLEEN; TARGET ORGAN; XENOGRAFT;

ANIMALS; ANTIBODIES; AVIDIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ORGAN SPECIFICITY; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

EID: 23944471731     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1811-2     Document Type: Article

References (33)

1. Goldenberg D. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
2. Chatal JF, Mahé M. Therapeutic use of radiolabelled antibodies. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment, 2nd ed. Edinburgh: Churchill Livingstone; 1998. p. 1101-14.
3. Mach JP, Pelegrin A, Buchegger F. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol. 1991;3:685-93.
4. Kobayashi H, Sakahara H, Endo K, Yao Z, Toyama S, Konishi J. Repeating the avidin chase markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity. Eur J Cancer 1995;31A:1689-96.
5. Wang Z, Garkavij M, Tennvall JG, Ohlsson T, Strand SE, Sjögren HO. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin. Cancer 2002;94:1287-92.
6. Goodwin DA, Meares CF. Pretargeting: general principles. Cancer 1996;80:2675-80.
7. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001;19:435-50.
8. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-302.
9. Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen positive patients. Cancer Res 1991;51:5960-6.
10. 90Y-DOTA-biotin. J Nucl Med 2000;41:131-40.
11. Yao Z, Zhang M, Kobayashi H, Sakahara H, Nakada H, Yamashina I, et al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med 1995;36:837-41.
12. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delage M, Barbet J. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990;50:3445-52.
13. Hosono M, Hosono M, Kraeber-Bodéré F, Devys A, Thedrez P, Fiche M, et al. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J Nucl Med 1998;39:1608-13.
14. Hosono M, Hosono M, Kraeber-Bodéré F, Devys A, Thedrez P, Faivre-Chauvet A, et al. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioionidated bivalent hapten. J Nucl Med 1999;40:1216-21.
15. Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, et al. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med 1998;39:1937-43.
16. Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, et al. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med 1999;40:198-204.
17. Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 2003;9:3973s-81s.
18. 131I-labeled bivalent hapten. J Nucl Med 2000;41:480-7.
19. Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, et al. Evaluation of a complementarity-determining regiongrafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s-45s.
20. Green NM. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem J 1965;94:23-4.
21. Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramine: 1,3,4,6 tetrachloro-3a,6a-diphenyl glycoluryl. Biophys Res Commun 1978;80:849-54.
22. Hillairet de Boisferon M, Raguin O, Dussaillant M, Rostene W, Barbet J, Gruaz-Guyon A. Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens. Bioconjug Chem 2000;11:452-60.
23. Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, et al. Radioimmunotherapy of small-cell lung carcinoma with the two-step method using a bispecific anti-CEA/anti-DTPA antibody and iodine-131-di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res 1999;5:3259s-67s.
24. Kraeber-Bodéré F, Bardet S, Hoefnagel C, Vieira MR, Vuillez JP, Murat A, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res 1999;5:3190s-8s.
25. Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 2003;9:3897s-913s.
26. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802-7.
27. 188Re-chi-BR96. J Nucl Med 1997;39:1207-10.
28. Schechter B, Silberman R, Arnon R, Wilchek M. Tissue distribution of avidin and streptavidin injected to mice: effect of avidin carbohydrate, steptavidin truncation and exogenous biotin. Eur J Biochem 1990;189:327-31.
29. Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998;78:189-97.
30. Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94:1349-57.
31. Dailey MO, Coleman CN, Fajardo LF. Splenic injury caused by therapeutic irradiation. Am J Surg Pathol 1981;5:325-31.
32. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
33. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-63.